載入...
BRG1/BRM and prohibitin are required for growth suppression by estrogen antagonists
Estrogen antagonists are universally employed in the breast cancer therapy, although antagonist therapy is limited by the inevitable development of cellular resistance. The molecular mechanisms by which these agents inhibit cellular proliferation in breast cancer cells are not fully defined. Recent...
Na minha lista:
| 發表在: | EMBO J |
|---|---|
| Main Authors: | , , |
| 格式: | Artigo |
| 語言: | Inglês |
| 出版: |
Nature Publishing Group
2004
|
| 主題: | |
| 在線閱讀: | https://ncbi.nlm.nih.govhttps://pmc.ncbi.nlm.nih.gov/articles/PMC419909/ https://ncbi.nlm.nih.govhttps://pubmed.ncbi.nlm.nih.gov/15141164/ https://ncbi.nlm.nih.govhttps://doi.org/10.1038/sj.emboj.7600231 |
| 標簽: |
添加標簽
沒有標簽, 成為第一個標記此記錄!
|